Nov. 23 Quick Takes: NIH panel says bamlanivimab should not be considered COVID-19 SOC; plus Eiger, Shionogi-Roche, Kiniksa, Schrödinger, Halozyme-Horizon and Immunicum-DCPrime

By Karen Tkach Tuzman and Paul Bonanos, Associate Editors

NIH panel says bamlanivimab should not be considered standard-of-care for COVID-19
NIH’s COVID-19 Treatment Guidelines Panel said there is not enough data to recommend